Cargando…

Extracellular ATP drives systemic inflammation, tissue damage and mortality

Systemic inflammatory response syndromes (SIRS) may be caused by both infectious and sterile insults, such as trauma, ischemia-reperfusion or burns. They are characterized by early excessive inflammatory cytokine production and the endogenous release of several toxic and damaging molecules. These ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Cauwels, A, Rogge, E, Vandendriessche, B, Shiva, S, Brouckaert, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973196/
https://www.ncbi.nlm.nih.gov/pubmed/24603330
http://dx.doi.org/10.1038/cddis.2014.70
_version_ 1782309670946340864
author Cauwels, A
Rogge, E
Vandendriessche, B
Shiva, S
Brouckaert, P
author_facet Cauwels, A
Rogge, E
Vandendriessche, B
Shiva, S
Brouckaert, P
author_sort Cauwels, A
collection PubMed
description Systemic inflammatory response syndromes (SIRS) may be caused by both infectious and sterile insults, such as trauma, ischemia-reperfusion or burns. They are characterized by early excessive inflammatory cytokine production and the endogenous release of several toxic and damaging molecules. These are necessary to fight and resolve the cause of SIRS, but often end up progressively damaging cells and tissues, leading to life-threatening multiple organ dysfunction syndrome (MODS). As inflammasome-dependent cytokines such as interleukin-1β are critically involved in the development of MODS and death in SIRS, and ATP is an essential activator of inflammasomes in vitro, we decided to analyze the ability of ATP removal to prevent excessive tissue damage and mortality in a murine LPS-induced inflammation model. Our results indeed indicate an important pro-inflammatory role for extracellular ATP. However, the effect of ATP is not restricted to inflammasome activation at all. Removing extracellular ATP with systemic apyrase treatment not only prevented IL-1β accumulation but also the production of inflammasome-independent cytokines such as TNF and IL-10. In addition, ATP removal also prevented systemic evidence of cellular disintegration, mitochondrial damage, apoptosis, intestinal barrier disruption and even mortality. Although blocking ATP receptors with the broad-spectrum P2 purinergic receptor antagonist suramin imitated certain beneficial effects of apyrase treatment, it could not prevent morbidity or mortality at all. We conclude that removal of systemic extracellular ATP could be a valuable strategy to dampen systemic inflammatory damage and toxicity in SIRS.
format Online
Article
Text
id pubmed-3973196
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39731962014-04-02 Extracellular ATP drives systemic inflammation, tissue damage and mortality Cauwels, A Rogge, E Vandendriessche, B Shiva, S Brouckaert, P Cell Death Dis Original Article Systemic inflammatory response syndromes (SIRS) may be caused by both infectious and sterile insults, such as trauma, ischemia-reperfusion or burns. They are characterized by early excessive inflammatory cytokine production and the endogenous release of several toxic and damaging molecules. These are necessary to fight and resolve the cause of SIRS, but often end up progressively damaging cells and tissues, leading to life-threatening multiple organ dysfunction syndrome (MODS). As inflammasome-dependent cytokines such as interleukin-1β are critically involved in the development of MODS and death in SIRS, and ATP is an essential activator of inflammasomes in vitro, we decided to analyze the ability of ATP removal to prevent excessive tissue damage and mortality in a murine LPS-induced inflammation model. Our results indeed indicate an important pro-inflammatory role for extracellular ATP. However, the effect of ATP is not restricted to inflammasome activation at all. Removing extracellular ATP with systemic apyrase treatment not only prevented IL-1β accumulation but also the production of inflammasome-independent cytokines such as TNF and IL-10. In addition, ATP removal also prevented systemic evidence of cellular disintegration, mitochondrial damage, apoptosis, intestinal barrier disruption and even mortality. Although blocking ATP receptors with the broad-spectrum P2 purinergic receptor antagonist suramin imitated certain beneficial effects of apyrase treatment, it could not prevent morbidity or mortality at all. We conclude that removal of systemic extracellular ATP could be a valuable strategy to dampen systemic inflammatory damage and toxicity in SIRS. Nature Publishing Group 2014-03 2014-03-06 /pmc/articles/PMC3973196/ /pubmed/24603330 http://dx.doi.org/10.1038/cddis.2014.70 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Original Article
Cauwels, A
Rogge, E
Vandendriessche, B
Shiva, S
Brouckaert, P
Extracellular ATP drives systemic inflammation, tissue damage and mortality
title Extracellular ATP drives systemic inflammation, tissue damage and mortality
title_full Extracellular ATP drives systemic inflammation, tissue damage and mortality
title_fullStr Extracellular ATP drives systemic inflammation, tissue damage and mortality
title_full_unstemmed Extracellular ATP drives systemic inflammation, tissue damage and mortality
title_short Extracellular ATP drives systemic inflammation, tissue damage and mortality
title_sort extracellular atp drives systemic inflammation, tissue damage and mortality
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973196/
https://www.ncbi.nlm.nih.gov/pubmed/24603330
http://dx.doi.org/10.1038/cddis.2014.70
work_keys_str_mv AT cauwelsa extracellularatpdrivessystemicinflammationtissuedamageandmortality
AT roggee extracellularatpdrivessystemicinflammationtissuedamageandmortality
AT vandendriesscheb extracellularatpdrivessystemicinflammationtissuedamageandmortality
AT shivas extracellularatpdrivessystemicinflammationtissuedamageandmortality
AT brouckaertp extracellularatpdrivessystemicinflammationtissuedamageandmortality